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AbstrACt
Introduction Use of albumin therapy is recommended 
for management of disease complications in cirrhosis. 
The effectiveness of albumin to prevent specific disease 
complications and death, however, is less clear.
Methods and analysis We will search Medline (Ovid), 
Embase (Ovid), Cochrane Hepato-Biliary Controlled Trials 
Register and Cochrane Central Register of Controlled 
Trials for published reports on randomised controlled 
trials and observational studies on the effectiveness of 
intravenous albumin therapy to prevent spontaneous 
bacterial peritonitis, renal dysfunction and death in 
cirrhotic patients. Two independent reviewers will 
screen the studies for eligibility, extract data and assess 
risk of bias and quality of evidence using Grading of 
Recommendations Assessment, Development and 
Evaluation system. Random effects meta-analyses will be 
performed when appropriate.
Ethics and dissemination As no primary data will be 
collected, a formal ethical approval is not required. We 
plan to publish the results of this study in a relevant peer-
reviewed journal or journals. The study results may also be 
presented at relevant conferences and meetings.
PrOsPErO registration number CRD42018100798.
bACkgrOund
More than 45 million people globally have 
cirrhosis and other severe forms of chronic 
liver disease.1 Driven by upward trend in 
obesity and alcohol consumption, the prev-
alence of liver disease is increasing. Chronic 
liver disease, due to fibrosis-causing inflam-
mation, usually progresses silently and 
slowly until the functioning of the liver is 
severely compromised and patients develop 
life-threatening complications such as ascites, 
spontaneous bacterial peritonitis (SBP) and 
renal dysfunction.
Albumin, the most abundant protein in 
human serum, has an important role in both 
maintaining fluid distribution in the body 
and potentially regulating immune response 
by binding and inactivating pro-inflamma-
tory molecules. In advanced liver disease, the 
synthesis of albumin in the liver is disturbed 
and both the quantity and functionality of 
albumin are substantially reduced.2 Treating 
patients with advanced liver disease with 
albumin infusions might improve both their 
ability to respond to infectious threats such 
as SBP and ability to restore adequate renal 
blood flow. Current clinical guidelines for 
albumin use in decompensated cirrhosis 
recommend the use of intravenous albumin 
infusions for management of ascites-related 
symptoms and paracentesis (removal of 
ascitic fluid) and for the management of SBP, 
renal dysfunction and variceal bleeding.3 
Routine albumin use is not recommended 
for the management of non-SBP infections.3
strengths and limitations of this study
 ► The broad range of outcomes included this review 
provide clinical practice and future guidelines a 
comprehensive picture of the effects of albumin 
therapy in cirrhosis.
 ► This study protocol has been developed according 
to the recommendations of the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses 
Protocols.
 ► The selection of studies, data extraction, the risk 
of bias and quality of evidence assessment us-
ing Grading of Recommendations Assessment, 
Development and Evaluation system will be con-
ducted by two independent authors.
 ► The eligibility criteria used may not result in the se-
lection of studies that are homogeneous in methods 
limiting the ability to draw reliable conclusions.
 ► Inclusion of studies regardless of the type of clinical 
setting or frequency of albumin delivery may limit 
the practical applicability of the summarised therapy 
effects to all clinical settings.
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rationale for the review
To avoid the potentially devastating consequences of 
the complications of cirrhosis, a better understanding of 
the effectiveness of available prevention and treatment 
strategies would be useful. While the use of albumin in 
the management of cirrhosis complications is currently 
recommended and widely employed, the effectiveness 
of albumin to prevent specific disease complications is 
less clear. Previous reviews have evaluated the effects of 
albumin therapy both in cirrhotic patients with infections 
(SBP and non-SBP)4 5 and in patients with cirrhosis-re-
lated ascites undergoing paracentesis.6 7 The reviews of 
albumin use in patients with infections,4 5 however, were 
written more than 5 years ago and new studies may have 
been conducted since. The most recent reviews in albumin 
use in paracentesis, published in 20127 and 2017,6 on the 
other hand, have come to contradictory conclusions on 
the albumin’s effectiveness to prevent of death after the 
procedure. None of the reviews included SBP as a study 
outcome and non-randomised studies were excluded.
The aim of this review is to improve our understanding 
of the effects of albumin use in cirrhosis by reviewing the 
currently available evidence and quantifying the effective-
ness of intravenous albumin therapy to prevent specific 
cirrhosis complications, SBP and renal dysfunction, and 
death. In contrast to previous reviews, we will also consider 
evidence from non-randomised studies. The results of 
this review may be used to inform future guidelines and 
clinical management of decompensated cirrhosis.
ObjECtIvEs
The aim of this review is to assess the effectiveness of intra-
venous albumin therapy to prevent SBP, renal dysfunction 
and death in adults with cirrhosis.
The objectives are:
 ► To assess the effectiveness of intravenous albumin 
therapy to prevent SBP in adults with cirrhosis and 
ascites (without SBP or non-SBP infection).
 ► To assess the effectiveness of intravenous albumin 
therapy to prevent renal dysfunction in adults with 
cirrhosis and ascites and/or infection (SBP or 
non-SBP infection).
 ► To assess the effectiveness of intravenous albumin 
therapy to prevent death in adults with cirrhosis and 
ascites and/or infection (SBP or non-SBP infection).
MEthOds
This study protocol has been developed following the 
recommendations of the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses Protocols 2015.8
Eligibility criteria
Types of studies
We will include randomised clinical trials (RCTs) and 
cohort (with comparison group/s) and case-control 
studies that investigate the effectiveness of intravenous 
albumin therapy in patients with cirrhosis and ascites 
and/or infection (SBP or non-SBP infection). We will 
include studies that have been published or accepted for 
publication in abstract form or in full. We will exclude 
review articles, meta-analyses, case reports, cross-sectional 
studies, animal studies, editorials, surveys of medical 
practice, clinical guidelines and studies that have been 
retracted from publication.
Types of participants
We will include studies that enrol more than 18-year-old 
adult patients with cirrhosis (regardless of severity or aeti-
ology by any classification) and ascites and/or infection 
(SBP or non-SBP infection), and more than 18-year-old 
adult patients with cirrhosis and ascites without obvious 
signs of baseline bacterial infection when an infection 
(SBP or non-SBP infection) is a study outcome.
Types of interventions
We will include studies that investigate the effects of intra-
venously administered albumin in any setting, of any 
dose, administration frequency and duration of therapy.
Types of comparators
We will include studies comparing albumin therapy to a 
placebo, an alternative intervention or no intervention.
Types of outcome measures
We will include studies that report on one or more of our 
primary outcomes and/or our secondary outcomes.
Primary outcomes
 ► SBP.
 ► Renal dysfunction (hepatorenal syndrome and other 
forms of renal dysfunction).
 ► All-cause mortality.
Secondary outcomes
 ► Non-SBP infections.
 ► Admission to intensive care.
 ► Adverse events (serious adverse events include any 
adverse event that at any dose results in death, is 
life-threatening, requires hospitalisation or prolongs 
existing hospitalisation, results in persistent or signifi-
cant disability or incapacity, is a congenital anomaly or 
birth defect, or seriously jeopardises the participant 
by requiring intervention to prevent one of the above 




To capture all relevant studies, we plan to search the 
following databases:
 ► The Cochrane Hepato-Biliary Controlled Trials 
Register.
 ► Cochrane Central Register of Controlled Trials.
 ► MEDLINE (Ovid).
 ► EMBASE (Ovid).
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Each database will be searched separately for studies 
published until the date of the search and the search 
strategy first developed in MEDLINE will be adapted to 
each database interface as appropriate. Where only a 
study protocol of an eligible study is found in the search, 
we will further search for the published study results 
and if necessary, contact the investigators named in the 
protocol. We plan to also search relevant studies from the 
reference lists of the eligible studies identified through 
the electronic searches and from the previous clinical 
guidelines for management of patients with cirrhosis.
search strategy
We will identify relevant articles by combining search 
terms for albumin and the eligible base conditions of the 
study participants: cirrhosis and ascites and/or infection 
(the search terms for SBP will capture both studies that 
specify the participants as having ‘SBP’, ‘non-SBP infec-
tions’ and ‘infections other than SBP’). The provisional 




Duplicate records of the same report will be removed 
using a reference management software (Mendeley). 
Report screening (both by title only and based on abstract 
and title), full-text review and extraction of data will be 
performed using a web-based, systematic review manage-
ment software (DistillerSR) with standardised online 
forms. Prior to the review, the forms will be piloted and 
revised if necessary.
Selection process
Articles identified through the search will be first screened 
by one reviewer (SH) by title only and then by two inde-
pendent reviewers (SH and CP) by abstract and title. 
Records with uncertain eligibility, or subject to disagree-
ment over eligibility, will always be included in the next 
screening stage until they reach the full-text review.
The full-text review will be completed by two indepen-
dent review authors (SH and CP). Disagreements over 
eligibility at this stage will be resolved by discussion and if 
required by consulting a third review author (AO or JR). 
Any uncertainties will be resolved by contacting the study 
investigators. Multiple, overlapping, or companion study 
reports representing the same study will be combined. If 
this is not possible, only the report that most closely fulfils 
our eligibility criteria will be included. The study selec-
tion process and reasons for excluding ineligible studies 
will be recorded and presented in a flow diagram.9
Data collection process
The data will be extracted independently and in duplicate 
by two review authors (SH and CP). Disagreements will 
be resolved by discussion and if required by consulting 
a third review author (AO or JR). Uncertainties will be 
resolved by contacting the study investigators.
data items
The data will be extracted on:
 ► Study participants: inclusion and exclusion criteria, 
recruitment/selection method and distribution of 
baseline characteristics (sex, age, aetiology, severity 
and characteristics of liver disease, comorbidi-
ties, abstinence, medication/treatment other than 
intervention).
 ► Interventions and comparison treatments: dose 
and frequency, size of intervention and comparison 
groups, length of follow-up.
 ► Outcomes: definition, time points, number of events, 
units of measurement, unadjusted and adjusted effect 
estimates, covariates used for adjustment, quantity of 
missing data and reasons for missingness, statistical 
methods.
 ► Study design: type of study, country, setting, year/s 
and duration of study.
 ► Study quality and study bias (as per the assessments 
specified below).
 ► Funding and competing interests.
Data on outcome measures will be extracted as reported 
and, if appropriate, transformed for presentation and 
analysis.
Outcomes and prioritisation
Our primary non-fatal outcomes, SBP and renal dysfunc-
tion, are common and serious cirrhosis complications. 
Cirrhotic patients may also experience other disease 
complications but given albumin is most commonly used 
clinically to improve blood volume and for infection treat-
ment/control, we have prioritised this common infectious 
complication (SBP) and a common consequence of the 
blood volume imbalance in cirrhosis (renal dysfunction).
Our secondary outcomes include non-SBP infec-
tions, admission to intensive care and adverse events. 
Table 1 Medline (Ovid) provisional search terms
Search concept Search terms
Albumin 1. Serum Albumin, Human/
2. Albumins/ad, tu, th 
[Administration & Dosage, 
Therapeutic Use, Therapy]
3. Albumin.mp.
4. 1 or 2 or 3
SBP 5. (‘spontaneous bacterial 
peritonitis’ or SBP).mp.
Ascites 6. exp ASCITES/
7. ascit*.mp.
8. 5 or 6 or 7
Cirrhosis 9. exp Liver Cirrhosis/
10. cirrho*.mp.
11. 9 or 10
Combined search 12. 4 and 8 and 11
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If albumin is effective in preventing SBP, it may also be 
effective against other infections. Due to its multiple 
functions in the body, albumin may provide protection 
against other life-threatening disease complications 
such as hepatic encephalopathy. In this review, all other 
potential complications are represented by the outcome 
‘admission to intensive care’. Previously reported serious 
adverse events in albumin therapy do include cardiac 
disorders and respiratory disorders (pulmonary oedema, 
bleeding from gastric varices) and so it is important to 
evaluate the therapy in context of any adverse events that 
may have been observed in these studies. The occurrence 
of complications and adverse events will be assessed after 
the start of the albumin treatment (after the delivery of 
the first dose of albumin).
Assessment of risk of bias in individual studies
To assess the risk of bias in RCTs, we will use the Cochrane 
Collaborations tool.10 The Newcastle-Ottawa Scale,11 will 
be used to assess the risk of bias in observational studies. 
Age, sex, severity and aetiology of cirrhosis, comorbidi-
ties, abstinence and treatment/medication other than 
the intervention/comparator will be considered the most 
important confounders in this assessment. Two indepen-
dent review authors (SH and CP) will make the risk of 
bias judgements together with a justification for each 
judgement (a direct quote from the study where possible) 
using standardised forms in a web-based, systematic review 
management software (DistillerSR). Disagreements will 
be resolved by discussion and if required by consulting a 
third review author (AO or JR). The assessments will be 
presented in figures that show the risk of bias in different 
risk areas at the level of individual studies and the risk of 
bias in different risk areas across the studies.
Assessment of bias in conducting the systematic review
We will report any differences between the methods of 
this pre-specified review protocol and the methods in 
conducting the complete review.
data synthesis
Criteria for quantitative data synthesis
We plan to perform a formal meta-analysis where >1 study 
per outcome is identified and we consider the studies 
similar enough to produce a meaningful pooled effect.
Measures of treatment effect
For dichotomous data, the treatment effect will be esti-
mated and presented as a risk ratio with 95% CIs. For 
time-to-event data, the effect will be estimated and the 
results presented as a log HR with 95% CI.
Unit of analysis issues
The outcomes will be analysed at the level of individual 
study participants.
Dealing with missing data
To obtain outcome data that are only partially reported 
(eg, where only the study abstract is available or an 
outcome is only reported in figure format) or are missing 
completely (outcome was set to be measured but was 
not reported on), we will contact the study investigators. 
Where possible, we will calculate missing SD from other 
statistics such as CIs or standard errors.
Assessment of heterogeneity
We plan to present a forest plot and calculate the formal 
heterogeneity variance statistics τ2, I2 and the Q-statistic 
for each of the review outcomes. We will regard hetero-
geneity as substantial if τ2 is greater than 0, I2 is more 
than 30% and the p value for Q-statistic is less than 0.10. 
We plan to explore the potential reasons for substantial 
heterogeneity using meta-regression (specified below).
Quantitative data synthesis
Statistical analyses will be carried out using Stata V.15 and 
RevMan. To account for the presence of heterogeneity, 
random effects meta-analysis will be used to summarise 
the average effects of albumin therapy on the defined 
outcomes. The results will be presented separately for 
patients without and with baseline SBP or non-SBP infec-
tion in forest plots with the average treatment effect and 
the estimates of τ² and I².
Subgroup analysis and investigation of heterogeneity
We plan to investigate the potential reasons for hetero-
geneity through random-effects meta-regression analyses. 
Meta-regression will be performed in case we identify ≥10 
studies per explanatory variable. Given the characteris-
tics and design of the included studies allow it, we will 
consider severity of cirrhosis and aetiology of cirrhosis as 
the variables.
Sensitivity analysis
In case the identified studies differ greatly in terms of risk 
of bias, we plan to conduct sensitivity analyses to investi-
gate the impact of excluding studies with high/unclear 
risk of bias on effect estimates. If the included studies 
report separately on patients with different cirrhosis aeti-
ologies or different degrees of cirrhosis severity, we plan 
to also investigate the impact of excluding patient popu-
lations with different aetiologies or severity on the effect 
estimates.
Qualitative data synthesis
We will provide a narrative study result summary for all 
outcomes. Study characteristics (participants, interven-
tions, comparators, outcomes, study design) of included 
studies will also be presented in tables categorised 
by outcome and by patients with and without SBP or 
non-SBP infection at baseline. For any outcomes where 
meta-analysis will not be carried out, the results will be 
presented in forest plots without the pooled effect esti-
mate. All results will be discussed in the context of the 
previously published systematic reviews and meta-analyses 
on the effects of albumin use in cirrhosis.
 o
n




pen: first published as 10.1136/bmjopen-2018-025664 on 29 January 2019. Downloaded from 
5Härmälä S, et al. BMJ Open 2019;9:e025664. doi:10.1136/bmjopen-2018-025664
Open access
Meta-bias(es)
Assessment of reporting biases across studies
We plan to investigate the presence of reporting bias using 
funnel plots. Formal test for the presence of reporting 
bias (Egger’s test) will be performed where there are ≥10 
studies in the analysis.
We plan to assess selective outcome reporting bias by 
comparing what the study set to measure and analyse 
with the results that were reported. Any trial protocol that 
can be identified will be used to aid this assessment. The 
presence of risk of selective outcome reporting bias will 
be evaluated using the Outcome Reporting Bias in Trials 
classification system.12
Confidence in cumulative evidence
We will assess and report the overall quality of the body of 
evidence for each review outcome using the Grading of 
Recommendations Assessment, Development and Evalu-
ation Working Group system.13 The study quality will be 
assessed by two independent review authors (SH and CP).
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